Bright Peak & Ajinomoto collaborate on immunocytokines

Bright Peak and Ajinomoto collaborate on immunocytokines

Bright Peak Therapeutics and Ajinomoto enter into research collaboration for novel immunocytokines
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

SAN DIEGO & TOKYO—Bright Peak Therapeutics Inc. and Ajinomoto Co., the owner of Ajinomoto Bio-Pharma Services, have announced a research collaboration and exclusive license agreement to incorporate AJICAP —  Ajinomoto’s proprietary site-specific bioconjugation technology — into the development of Bright Peak Immunocytokines.

Bright Peak Therapeutics uses ligation technology to chemically synthesize therapeutic cytokines by ligating customized peptide segments together. This proprietary platform reportedly provides the flexibility to both tune and enhance cytokine biology through affinity modification and orthogonal, site-specific conjugation. 

“We are delighted to announce the collaboration with Ajinomoto Co. to develop our proprietary Immunocytokines using AJICAP technology. The AJICAP conjugation technology is ideally suited to conjugate our enhanced cytokines as payloads to antibodies in the cancer and autoimmune field,” noted Dr. Sef Kurstjens, president and CEO of Bright Peak.

AJICAP is a proprietary site-specific bioconjugation technology compatible with commonly-used antibody isotypes. The AJICAP technology has the advantage of an “off-the-shelf” feature — allowing any therapeutic antibody at any stage of development to be conjugated to drug-payloads of choice, without the need for antibody engineering or cell line development.

“Ajinomoto Co. and Ajinomoto Bio-Pharma Services are very excited to collaborate with Bright Peak in the development of targeted Immunocytokines,” added Dr. Tatsuya Okuzumi, associate general manager of the Research and Business Planning Department at Ajinomoto. “The ability to direct potent, homogeneous immune-signaling molecules to tumors and the tumor microenvironment may provide enhanced antitumor clinical benefit through immune cell cytotoxic activity. The combination of Bright Peak’s cytokine payloads with Ajinomoto Co.’s AJICAP opens up a wide range of oncology applications, and may be harnessed to provide a clinical benefit to patients.” 

As part of the collaboration and license agreement, the AJICAP technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies — creating novel, proprietary Bright Peak Immunocytokines. These Immunocytokines will allow tissue- and cell-specific targeting of the cytokine payload, with added potential for synergistic efficacy through potency-enhancing avidity effects. 

Bright Peak will receive exclusive worldwide rights to use the AJICAP technology for the conjugation of certain cytokine payloads — including, but not limited to, interleukin-2 — as part of the agreement, which covers the development of multiple Immunocytokine molecules. Bright Peak will make an exclusivity payment, and Ajinomoto Co. is eligible to receive development, regulatory, and commercial milestone payments, as well as royalties on commercial sales.

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue